Across TCGA pan-cancer cohorts, MIR659 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MIR659 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR659 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR659 expression acts as an unfavorable survival marker, although some lineages such as UCS and CHOL show a favorable association.

LIHC, UCS, and BLCA are the cancer types where MIR659 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.462	0.648	.003	36	view →
UCS	DFS	Quartile	II,III,IV	0.684	0.201	.004	34	view →
BLCA	DFS	Quartile	IV	0.315	0.538	.003	31	view →
CHOL	OS	Tertile	All	0.775	0.145	.005	27	view →
DLBC	DFS	Median	II,III,IV	0.477	1.000	.005	23	view →
LUAD	DFS	Quartile	IV	0.339	0.660	.022	18	view →
STAD	OS	Median	III,IV	0.615	0.424	.011	15	view →
LUSC	OS	Median	II,III,IV	0.817	0.664	.002	14	view →
COAD	DFS	Median	IV	0.216	0.442	.013	13	view →
LGG	DFS	Tertile	All	0.607	0.365	.002	10	view →
ACC	OS	Median	All	0.896	0.719	.018	8	view →
THCA	DFS	Median	III,IV	0.262	0.839	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

Exploration

Same gene, other analysis: MIR659 tumor-vs-normal RNA expression · all MIR659 data types